Hypercortisolism is increasingly recognized as an underdiagnosed contributor to resistant hypertension, cardiovascular disease, and broader cardiometabolic dysfunction. In this Peer Exchange, a panel of expert cardiologists discusses the evolving evidence linking cortisol excess to difficult-to-control hypertension, explores practical approaches to patient identification and screening, and reviews the implications of recent studies, including MOMENTUM and CATALYST. The faculty examine emerging treatment strategies, the role of multidisciplinary care, and opportunities to improve long-term outcomes through earlier recognition and targeted management of hypercortisolism. Throughout the discussion, they highlight how increasing awareness of cortisol excess may help clinicians uncover a potentially reversible driver of cardiovascular risk in everyday practice.
In this episode, ‘The Challenge of Resistant Hypertension,’ features the panelists discussing persistent barriers to blood pressure control, evolving hypertension management strategies, and the importance of recognizing secondary causes of resistant hypertension. They also explore how missed opportunities for diagnosis may contribute to ongoing cardiovascular risk in clinical practice.
In, ‘Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk’, panelists will continue their discussion on hypercortisolism and highlight how cortisol excess can contribute to hypertension and cardiovascular risk even in the absence of classic Cushing syndrome features. They also explore emerging evidence linking hypercortisolism to adverse cardiometabolic outcomes and the implications for cardiovascular practice.
In ‘Prevalence of Hypercortisolism in Resistant Hypertension,’ our panel explores the growing recognition of hypercortisolism as an important contributor to resistant hypertension, cardiovascular disease, and cardiometabolic dysfunction.
This episode, titled ‘Recognizing Hypercortisolism in Cardiovascular Practice,’ features panelists discussing the patient presentations that should raise suspicion for underlying hypercortisolism in patients with hypertension and cardiovascular disease.
In this episode, ‘Hypercortisolism and Other Secondary Causes of Hypertension,’ the panelists explore how cardiologists should think about hypercortisolism in the context of other secondary causes of hypertension, particularly primary aldosteronism.
In ‘Hypercortisolism Screening in Cardiology Practice,’ our panel explores the evolving role of cardiologists in identifying patients at risk for hypercortisolism and initiating appropriate screening evaluations.
This episode, titled ‘Guidelines and Barriers to Hypercortisolism Screening in Cardiology,’ features panelists discussing how recent clinical evidence and updated expert recommendations may influence the recognition and screening of hypercortisolism in patients with resistant hypertension and cardiovascular disease.
In this episode, ‘Hypercortisolism Insights from MOMENTUM and CATALYST Trials,’ the panelists explore the design, findings, and clinical implications of the MOMENTUM and CATALYST studies and discuss how emerging evidence is reshaping the understanding of hypercortisolism in resistant hypertension and difficult-to-control type 2 diabetes.
In ‘Management and Treatment Goals in Hypercortisolism,’ our panel explores practical approaches to managing patients with hypercortisolism-associated hypertension following diagnosis and discusses the importance of addressing the underlying cause of disease.
This episode, titled ‘Emerging Therapies for Hypercortisolism,’ features panelists discussing the evolving treatment landscape for hypercortisolism and the growing body of research aimed at improving outcomes for patients with resistant hypertension, diabetes, and other cardiometabolic complications.
In this episode, ‘The Future of Hypercortisolism Care in Cardiology,’ the panelists explore how increasing awareness of hypercortisolism may reshape cardiovascular practice, education, and multidisciplinary care models.
In the final episode, ‘Hypercortisolism Recognition and Action in Resistant Hypertension,’ the panelists explored key takeaways from their discussion on the evolving role of hypercortisolism in resistant hypertension and cardiometabolic disease.
